Breast - ACE-Breast 03

Ambrx "ACE-Breast 03"

Objective

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinibcontaining Regimens

Principal Investigator(s)

David Chan, MD

Clinical Trial Categories

• UCLA Trio Clinical Trials